IRIS Accounts Production v26.1.10.61 11216286 Board of Directors 1.4.25 31.3.26 31.3.26 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh112162862025-03-31112162862026-03-31112162862025-04-012026-03-31112162862024-03-31112162862024-04-012025-03-31112162862025-03-3111216286ns15:EnglandWales2025-04-012026-03-3111216286ns14:PoundSterling2025-04-012026-03-3111216286ns10:Director12025-04-012026-03-3111216286ns10:PrivateLimitedCompanyLtd2025-04-012026-03-3111216286ns10:SmallEntities2025-04-012026-03-3111216286ns10:AuditExempt-NoAccountantsReport2025-04-012026-03-3111216286ns10:SmallCompaniesRegimeForDirectorsReport2025-04-012026-03-3111216286ns10:SmallCompaniesRegimeForAccounts2025-04-012026-03-3111216286ns10:FullAccounts2025-04-012026-03-311121628612025-04-012026-03-3111216286ns10:Director22025-04-012026-03-3111216286ns10:RegisteredOffice2025-04-012026-03-3111216286ns5:CurrentFinancialInstruments2026-03-3111216286ns5:CurrentFinancialInstruments2025-03-3111216286ns5:Non-currentFinancialInstruments2026-03-3111216286ns5:Non-currentFinancialInstruments2025-03-3111216286ns5:ShareCapital2026-03-3111216286ns5:ShareCapital2025-03-3111216286ns5:RetainedEarningsAccumulatedLosses2026-03-3111216286ns5:RetainedEarningsAccumulatedLosses2025-03-3111216286ns5:NetGoodwill2025-04-012026-03-3111216286ns5:IntangibleAssetsOtherThanGoodwill2025-04-012026-03-3111216286ns5:NetGoodwill2025-03-3111216286ns5:NetGoodwill2026-03-3111216286ns5:NetGoodwill2025-03-3111216286ns5:LandBuildings2025-03-3111216286ns5:PlantMachinery2025-03-3111216286ns5:LandBuildings2025-04-012026-03-3111216286ns5:PlantMachinery2025-04-012026-03-3111216286ns5:LandBuildings2026-03-3111216286ns5:PlantMachinery2026-03-3111216286ns5:LandBuildings2025-03-3111216286ns5:PlantMachinery2025-03-3111216286ns5:WithinOneYearns5:CurrentFinancialInstruments2026-03-3111216286ns5:WithinOneYearns5:CurrentFinancialInstruments2025-03-3111216286ns5:Non-currentFinancialInstrumentsns5:BetweenOneTwoYears2026-03-3111216286ns5:Non-currentFinancialInstrumentsns5:BetweenOneTwoYears2025-03-3111216286ns5:Non-currentFinancialInstrumentsns5:BetweenTwoFiveYears2026-03-3111216286ns5:Non-currentFinancialInstrumentsns5:BetweenTwoFiveYears2025-03-3111216286ns5:MoreThanFiveYearsns5:Non-currentFinancialInstruments2026-03-3111216286ns5:MoreThanFiveYearsns5:Non-currentFinancialInstruments2025-03-3111216286ns5:WithinOneYear2026-03-3111216286ns5:WithinOneYear2025-03-3111216286ns5:BetweenOneFiveYears2026-03-3111216286ns5:BetweenOneFiveYears2025-03-3111216286ns5:MoreThanFiveYears2026-03-3111216286ns5:MoreThanFiveYears2025-03-3111216286ns5:AllPeriods2026-03-3111216286ns5:AllPeriods2025-03-3111216286ns5:DeferredTaxation2025-04-012026-03-3111216286ns5:DeferredTaxation2026-03-3111216286ns5:RetainedEarningsAccumulatedLosses2025-03-3111216286ns5:RetainedEarningsAccumulatedLosses2025-04-012026-03-31
REGISTERED NUMBER: 11216286 (England and Wales)



















Unaudited Financial Statements

for the Year Ended 31 March 2026

for

PHARMACO HALESOWEN LIMITED

PHARMACO HALESOWEN LIMITED (REGISTERED NUMBER: 11216286)






Contents of the Financial Statements
for the Year Ended 31 March 2026




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


PHARMACO HALESOWEN LIMITED

Company Information
for the Year Ended 31 March 2026







DIRECTORS: Mushtaq Jafferali Ismail
Hasnain Fidahussein Asaria





REGISTERED OFFICE: Unit 4, Boultbee Business Units
Nechells Place
Birmingham
West Midlands
B7 5AR





REGISTERED NUMBER: 11216286 (England and Wales)





ACCOUNTANTS: Brindleys Limited
2 Wheeleys Road
Edgbaston
Birmingham
West Midlands
B15 2LD

PHARMACO HALESOWEN LIMITED (REGISTERED NUMBER: 11216286)

Balance Sheet
31 March 2026

2026 2025
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 179,197 238,857
Tangible assets 5 2,752 1,447
181,949 240,304

CURRENT ASSETS
Stocks 6 27,147 26,903
Debtors 7 116,135 114,147
Cash at bank and in hand 135,648 100,793
278,930 241,843
CREDITORS
Amounts falling due within one year 8 207,973 259,164
NET CURRENT ASSETS/(LIABILITIES) 70,957 (17,321 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

252,906

222,983

CREDITORS
Amounts falling due after more than one
year

9

(108,498

)

(121,225

)

PROVISIONS FOR LIABILITIES 11 (369 ) -
NET ASSETS 144,039 101,758

CAPITAL AND RESERVES
Called up share capital 100 100
Retained earnings 12 143,939 101,658
144,039 101,758

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2026.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2026 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

PHARMACO HALESOWEN LIMITED (REGISTERED NUMBER: 11216286)

Balance Sheet - continued
31 March 2026


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 10 August 2026 and were signed on its behalf by:





Mushtaq Jafferali Ismail - Director


PHARMACO HALESOWEN LIMITED (REGISTERED NUMBER: 11216286)

Notes to the Financial Statements
for the Year Ended 31 March 2026

1. STATUTORY INFORMATION

Pharmaco Halesowen Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Goodwill
Goodwill, being the amount paid in connection with the acquisition of a business in 2019, is being amortised evenly over its estimated useful life of ten years.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Motor Vehicle - 25% on reducing balance

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

PHARMACO HALESOWEN LIMITED (REGISTERED NUMBER: 11216286)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2026

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 10 (2025 - 9 ) .

4. INTANGIBLE FIXED ASSETS
Goodwill
£   
COST
At 1 April 2025
and 31 March 2026 596,604
AMORTISATION
At 1 April 2025 357,747
Charge for year 59,660
At 31 March 2026 417,407
NET BOOK VALUE
At 31 March 2026 179,197
At 31 March 2025 238,857

5. TANGIBLE FIXED ASSETS
Plant and
Land and machinery
buildings etc Totals
£    £    £   
COST
At 1 April 2025 1 3,978 3,979
Additions - 2,153 2,153
Disposals - (1,900 ) (1,900 )
At 31 March 2026 1 4,231 4,232
DEPRECIATION
At 1 April 2025 1 2,531 2,532
Charge for year - 485 485
Eliminated on disposal - (1,537 ) (1,537 )
At 31 March 2026 1 1,479 1,480
NET BOOK VALUE
At 31 March 2026 - 2,752 2,752
At 31 March 2025 - 1,447 1,447

6. STOCKS
2026 2025
£    £   
Stocks 27,147 26,903

PHARMACO HALESOWEN LIMITED (REGISTERED NUMBER: 11216286)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2026

7. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2026 2025
£    £   
Trade debtors 101,790 89,894
VAT 12,983 22,556
Prepayments 1,362 1,697
116,135 114,147

8. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2026 2025
£    £   
Bank loans and overdrafts 12,277 11,828
Trade creditors 121,803 126,046
Amounts owed to group undertakings 19,454 41,441
Tax 33,575 33,970
Social security and other taxes 685 523
Other creditors 81 170
Directors' current accounts 13,373 38,373
Accrued expenses 6,725 6,813
207,973 259,164

9. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
2026 2025
£    £   
Bank loans - 1-2 years 12,277 11,828
Bank loans - 2-5 years 36,832 35,485
Bank loans more 5 yr by instal 59,389 73,912
108,498 121,225

Amounts falling due in more than five years:

Repayable by instalments
Bank loans more 5 yr by instal 59,389 73,912

10. LEASING AGREEMENTS

Minimum lease payments under non-cancellable operating leases fall due as follows:
2026 2025
£    £   
Within one year 9,500 9,500
Between one and five years 38,000 38,000
In more than five years 31,192 40,692
78,692 88,192

PHARMACO HALESOWEN LIMITED (REGISTERED NUMBER: 11216286)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2026

11. PROVISIONS FOR LIABILITIES
2026 2025
£    £   
Deferred tax 369 -

Deferred
tax
£   
Provided during year 369
Balance at 31 March 2026 369

12. RESERVES
Retained
earnings
£   

At 1 April 2025 101,658
Profit for the year 42,281
At 31 March 2026 143,939